NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

KALA BIO, Inc. (KALA) Stock Analysis

KALA BIO, Inc. (KALA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KALA

$0.19

+$0.00 (+0.58%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KALA with… →

KALA Key Statistics

As of Oct 21, 2026
Trading
Open
$0.20
Previous Close
$0.19
Day's Range
0.18–0.21
52-Week Range
0.12–95.50
Volume
234.81K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−2.41
Valuation
Market Cap
$3.69M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−10.71
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.98M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.34M
1-Year Return
−99.59%
Dividend and dates
Avg Volume
1.50M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KALA closed at $0.19, −99.59% over 1 year.

KALA BIO, Inc. (KALA) has a market capitalization of $3.69M.

In fiscal 2025, KALA reported revenue of $0.00.

KALA Stock Return by Calendar Year

KALA BIO, Inc. (KALA) return since Jul 2017: what $10,000 became

1 year
$10,000 $41
−99.59%
5 years
$10,000 $0.40
−99.996%
Since Jul 2017
$10,000 $0.04
−99.9996%

If you had invested $10,000 in KALA BIO, Inc. (KALA) at the close on July 20, 2017, the earliest close on record here, it would have been worth $0.04 at the close on October 21, 2026: −99.9996% in total, −73.81% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−99.31%
2025−91.99%
2024−0.86%
2023−81.65%
2022−36.94%
2021−82.15%
2020+83.74%
2019−24.54%
2018−73.55%
2017 (partial year)+0.00%

As of October 21, 2026.

KALA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.98M—
2024$0.00−$38.51M—
2023$0.00−$42.20M—
2022$3.89M−$44.82M−1,151.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$39.03M−$26.98M—
2024$0.00—−$34.24M−$38.51M—
2023$0.00$0.00−$34.33M−$42.20M—
2022$3.89M$1.33M−$81.36M−$44.82M−1,151.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values KALA BIO, Inc. (KALA) at $3.69M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 6.

The most recent close on file for KALA is $0.19, dated October 21, 2026. That is $0.00 (+0.58%) against the previous close. The 52-week range on file runs from $0.12 to $95.50. The latest close sits 65.91% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $26.98M. Trailing earnings per share are −10.71.

Across the 4 fiscal years on file, revenue moves from $3.89M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −99.59%. Across 5 years the annualized return works out at −86.79%. The reported beta is −2.41. Daily returns over the trailing 9 years annualize to a volatility of 134.19%.

Growth & Income

The record shows no dividend for KALA.

2026 is still running; the total return is −99.31% year to date. The strongest complete calendar year on file is 2020 at +83.74%; the weakest is 2025 at −91.99%. Of the 8 complete calendar years on file, 1 finished higher.

Peer Comparison

KALA BIO, Inc. (KALA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
KALA BIO, Inc. KALA $3.69M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. KALA BIO, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About KALA BIO, Inc.

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Visit website →